AKT1 and Alzheimer disease: Network pharmacology was conducted to reveal the mechanism involved in the improvement of AD and PD symptoms and found five critical targets, including caspase-3 (CASP3), caspase-8 (CASP8), mitogen-activated protein kinase 8 (MAPK8), mitogen-activated protein kinase 14 (MAPK14) and RAC-alpha serine/threonine-protein kinase (AKT1) [24].